Search research articles
Contact Us
Filters
Showing results (41-50 of 78) with videos related to
Page
of 8
Sort By:
Sleep Medicine
|
October 17, 2022
Randomized, crossover, open-label study of the relative bioavailability and safety of FT218, a once-nightly sodium oxybate formulation: Phase 1 study in healthy volunteers
Richard Bogan, Michael J Thorpy, John W Winkelman, et al.
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine
|
December 9, 2009
Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion
Y Grace Wang, Todd J Swick, Lawrence P Carter, et al.
Nature and Science of Sleep
|
April 5, 2022
Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution: A Lower-Sodium Alternative for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy
Yves Dauvilliers, Richard K Bogan, Karel Šonka, et al.
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine
|
September 8, 2011
Sodium oxybate: updates and correction to previously published safety data
Y Grace Wang, Todd J Swick, Lawrence P Carter, et al.
Sleep Medicine
|
March 15, 2021
Efficacy of pitolisant in patients with high burden of narcolepsy symptoms: pooled analysis of short-term, placebo-controlled studies
Craig W Davis, Ulf Kallweit, Jean-Charles Schwartz, et al.
Journal of Comparative Effectiveness Research
|
August 1, 2024
Improvements in daytime sleepiness and disrupted nighttime sleep with once-nightly sodium oxybate in people with narcolepsy type 1 and type 2: a plain language summary
Yves Dauvilliers, Thomas Roth, Richard Bogan, et al.
Sleep Medicine: X
|
April 11, 2024
Cataplexy response with extended-release once-nightly sodium oxybate: Post hoc responder analyses from the phase 3 REST-ON clinical trial
Michael J Thorpy, Clete A Kushida, Richard Bogan, et al.
Advances in Therapy
|
May 27, 2023
Clinician Preferences for Oxybate Treatment for Narcolepsy: Survey and Discrete Choice Experiment
Anne Marie Morse, Lois Krahn, Julie Flygare, et al.
Sleep Medicine
|
September 25, 2024
Efficacy of once-nightly sodium oxybate (FT218) on daytime symptoms in individuals with narcolepsy with or without concomitant alerting agent use: A post hoc analysis from the phase 3 REST-ON trial
Yves Dauvilliers, Thomas Roth, Richard Bogan, et al.
Drugs - Real World Outcomes
|
January 13, 2021
The Xyrem<sup>®</sup> (Sodium Oxybate) Risk Evaluation and Mitigation Strategy (REMS) Program in the USA: Results From 2016 to 2017
Michael J Strunc, Jed Black, Prasheel Lillaney, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 78) with videos related to
Sort By:
Page
of 8
Sleep Medicine
|
October 17, 2022
Randomized, crossover, open-label study of the relative bioavailability and safety of FT218, a once-nightly sodium oxybate formulation: Phase 1 study in healthy volunteers
Richard Bogan, Michael J Thorpy, John W Winkelman, et al.
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine
|
December 9, 2009
Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion
Y Grace Wang, Todd J Swick, Lawrence P Carter, et al.
Nature and Science of Sleep
|
April 5, 2022
Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution: A Lower-Sodium Alternative for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy
Yves Dauvilliers, Richard K Bogan, Karel Šonka, et al.
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine
|
September 8, 2011
Sodium oxybate: updates and correction to previously published safety data
Y Grace Wang, Todd J Swick, Lawrence P Carter, et al.
Sleep Medicine
|
March 15, 2021
Efficacy of pitolisant in patients with high burden of narcolepsy symptoms: pooled analysis of short-term, placebo-controlled studies
Craig W Davis, Ulf Kallweit, Jean-Charles Schwartz, et al.
Journal of Comparative Effectiveness Research
|
August 1, 2024
Improvements in daytime sleepiness and disrupted nighttime sleep with once-nightly sodium oxybate in people with narcolepsy type 1 and type 2: a plain language summary
Yves Dauvilliers, Thomas Roth, Richard Bogan, et al.
Sleep Medicine: X
|
April 11, 2024
Cataplexy response with extended-release once-nightly sodium oxybate: Post hoc responder analyses from the phase 3 REST-ON clinical trial
Michael J Thorpy, Clete A Kushida, Richard Bogan, et al.
Advances in Therapy
|
May 27, 2023
Clinician Preferences for Oxybate Treatment for Narcolepsy: Survey and Discrete Choice Experiment
Anne Marie Morse, Lois Krahn, Julie Flygare, et al.
Sleep Medicine
|
September 25, 2024
Efficacy of once-nightly sodium oxybate (FT218) on daytime symptoms in individuals with narcolepsy with or without concomitant alerting agent use: A post hoc analysis from the phase 3 REST-ON trial
Yves Dauvilliers, Thomas Roth, Richard Bogan, et al.
Drugs - Real World Outcomes
|
January 13, 2021
The Xyrem<sup>®</sup> (Sodium Oxybate) Risk Evaluation and Mitigation Strategy (REMS) Program in the USA: Results From 2016 to 2017
Michael J Strunc, Jed Black, Prasheel Lillaney, et al.
Page
of 8